SCHEMBL2409142

SCHEMBL2409142

Nc1cccc2oc(-c3ccccc3)cc(=O)c12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.75
ESR2 Q92731 1/20 0.75
AR P10275 7/20 0.67
CYP3A4 P08684 7/20 0.67
MAPT P10636 6/20 0.67
ALDH1A1 P00352 4/20 0.67
SMN1; SMN2 Q16637 4/20 0.67
CYP1B1 Q16678 4/20 0.67
CYP1A1 P04798 4/20 0.67
CYP1A2 P05177 4/20 0.67
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
FTO Q9C0B1 3/20 0.67
ALOX15 P16050 2/20 0.67
PKM P14618 1/20 0.67
HPGD P15428 5/20 0.61
TP53 P04637 4/20 0.61
KDM4E B2RXH2 3/20 0.61
HSD17B10 Q99714 3/20 0.61
ABCG2 Q9UNQ0 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560703 0.89 ESR1 (0.78) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10433065 0.87 LCK (0.67) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432596 0.86 ESR1 (1.00) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432799 0.86 ESR1 (0.74) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432664 0.84 ESR1 (0.76) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432657 0.83 ESR1 (0.61) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432916 0.83 ESR1 (0.78) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432638 0.82 ESR1 (0.68) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432584 0.82 ESR1 (0.68) ESR1ESR2ARCYP3A4MAPT
SCHEMBL10432678 0.82 AR (0.71) ESR1ESR2ARCYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0755928-B1 5-AMINOFLAVONE DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2002-04-10 EP claimed
EP-0638566-B1 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent KYOWA HAKKO KOGYO KK (JP) 1999-01-07 EP claimed
EP-0755928-A1 5-AMINOFLAVONE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-01-29 EP claimed
US-5539112-A 5-aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-07-23 US claimed
EP-0638566-A1 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-02-15 EP claimed
JP-7109268-A None JP disclosed
US-20130177904-A1 ARNT ISOFORM 3 AS A PREDICTOR OF AMINOFLAVONE RESPONSIVENESS IN CANCER CELLS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2013-07-11 US disclosed
WO-2011106373-A2 ARNT ISOFORM 3 AS A PREDICTOR OF AMINOFLAVONE RESPONSIVENESS IN CANCER CELLS UNIVERSITY OF MARYLAND, BALTIMORE (US) 2011-09-01 WO disclosed
EP-1373243-B1 AMINOFLAVONE COMPOUNDS, COMPOSITIONS, AND USE THEREOF US GOV HEALTH & HUMAN SERV (US) 2005-06-22 EP disclosed
US-20040019227-A1 Aminoflavone compounds, compositions, and methods of use KYOWA HAKKO KIRIN CO., LTD. (JP) 2004-01-29 US disclosed
EP-1373243-A1 AMINOFLAVONE COMPOUNDS, COMPOSITIONS, AND USE THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-01-02 EP disclosed
WO-2002081462-A1 AMINOFLAVONE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2002-10-17 WO disclosed
EP-0638566-A1 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-02-15 EP disclosed
EP-0638566-A1 5-Aminoflavone derivatives, their preparation and their use as antibacterial, anti-estrogenic and/or antitumor agent KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-02-15 EP disclosed
EP-0556720-A1 5-Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-08-25 EP disclosed
EP-0556720-A1 5-Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-08-25 EP disclosed
EP-0556720-A1 5-Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-08-25 EP disclosed
EP-0374789-A1 5- Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-06-27 EP disclosed
EP-0374789-A1 5- Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-06-27 EP disclosed
EP-0374789-A1 5- Aminoflavone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019227-A1 Aminoflavone compounds, compositions, and methods of use HDGF, ERBB2, ING2 ESR1 2547/4885ESR2 299/4885AR 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.